PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-55.89%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-45.42%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-98.53%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-102.86%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-117.37%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-117.36%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-117.36%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
148.41%
10Y revenue/share CAGR above 1.5x 4997.T's 17.57%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
137.49%
Positive 5Y CAGR while 4997.T is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
70.80%
3Y revenue/share CAGR above 1.5x 4997.T's 1.56%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
10Y OCF/share CAGR in line with 4997.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
75.64%
Positive 10Y CAGR while 4997.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.
68.35%
Positive 5Y CAGR while 4997.T is negative. John Neff might view this as a strong mid-term relative advantage.
-112.07%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
336.54%
Equity/share CAGR of 336.54% while 4997.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
48.43%
5Y equity/share CAGR above 1.5x 4997.T's 3.89%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
32.40%
Positive short-term equity growth while 4997.T is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.24%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
11.79%
We show growth while 4997.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-5.75%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.79%
We’re deleveraging while 4997.T stands at 0.26%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-11.69%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.